- Home
- DENN vs ACIU Comparison
DENN vs ACIU Comparison
Compare DENN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DENN
- ACIU
- Stock Information
- Founded
- DENN 1953
- ACIU 2003
- Country
- DENN United States
- ACIU Switzerland
- Employees
- DENN N/A
- ACIU N/A
- Industry
- DENN Restaurants
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- DENN Consumer Discretionary
- ACIU Health Care
- Exchange
- DENN Nasdaq
- ACIU Nasdaq
- Market Cap
- DENN 203.4M
- ACIU 189.1M
- IPO Year
- DENN 1989
- ACIU 2016
- Fundamental
- Price
- DENN $4.16
- ACIU $2.04
- Analyst Decision
- DENN Strong Buy
- ACIU Strong Buy
- Analyst Count
- DENN 6
- ACIU 1
- Target Price
- DENN $7.46
- ACIU $12.00
- AVG Volume (30 Days)
- DENN 615.7K
- ACIU 123.5K
- Earning Date
- DENN 07-29-2025
- ACIU 08-05-2025
- Dividend Yield
- DENN N/A
- ACIU N/A
- EPS Growth
- DENN N/A
- ACIU N/A
- EPS
- DENN 0.33
- ACIU N/A
- Revenue
- DENN $453,997,000.00
- ACIU $32,014,254.00
- Revenue This Year
- DENN $7.51
- ACIU N/A
- Revenue Next Year
- DENN $1.98
- ACIU $533.21
- P/E Ratio
- DENN $12.83
- ACIU N/A
- Revenue Growth
- DENN N/A
- ACIU 91.20
- 52 Week Low
- DENN $2.85
- ACIU $1.43
- 52 Week High
- DENN $7.73
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- DENN 48.24
- ACIU 54.21
- Support Level
- DENN $4.04
- ACIU $1.94
- Resistance Level
- DENN $4.48
- ACIU $2.15
- Average True Range (ATR)
- DENN 0.21
- ACIU 0.16
- MACD
- DENN -0.02
- ACIU -0.00
- Stochastic Oscillator
- DENN 28.57
- ACIU 72.22
About DENN Denny's Corporation
Denny's Corp is one of America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.